Arcturus Gears Up to Report Q3 Earnings: Here's What to Expect
On ARCT's third-quarter 2024 earnings call, investors' focus is likely to be on the upcoming launch of its COVID-19 vaccine, Kostaive and other pipeline updates.
Pharmaceutical Technology27d
A slow start for self-amplifying mRNA vaccines
A year after the first samRNA vaccine approval, experts say others are likely to face scientific and regulatory hurdles.
Yahoo Finance27d
A slow start for self-amplifying mRNA vaccines
In November 2023, Kostaive (ARCT-154), developed by Arcturus Therapeutics and CSL Behring, was the first samRNA vaccine to gain full marketing approval in Japan to treat Wuhan-Hu-1 strain SARS-Cov-2.
The Lancet27d
Steps towards licensure of self-amplifying RNA vaccines
Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. mRNA-based vaccines, as ...